Trinity Capital Inc. (NASDAQ: TRIN) Sees Positive Outlook from UBS with a $17 Price Target

• UBS sets a price target of $17 for Trinity Capital Inc. (NASDAQ: TRIN), indicating a potential upside of 14.17%.

• TRIN invests $130 million in Candel Therapeutics to support the development of cancer-fighting viral immunotherapies.

• The stock shows a slight increase to $14.98, with a trading volume of 365,074 shares, reflecting active investor interest.

Trinity Capital Inc. (NASDAQ: TRIN) is an alternative asset manager known for providing growth capital to innovative companies. Recently, UBS set a price target of $17 for TRIN, suggesting a potential price increase of 14.17% from its current price of $14.89. This target reflects optimism about TRIN's future performance and growth prospects.

TRIN has made a notable investment of $130 million in Candel Therapeutics, a biopharmaceutical company focused on developing cancer-fighting viral immunotherapies. This financial commitment supports Candel's efforts to advance their pipeline of cancer treatments, potentially enhancing TRIN's portfolio and future earnings.

Currently, TRIN's stock is priced at $14.98, showing a slight increase of 1.01% with a price change of $0.15. The stock has fluctuated between $14.72 and $15.015 today, indicating some volatility. Over the past year, TRIN's stock has ranged from a low of $12.50 to a high of $16.82.

TRIN's market capitalization is approximately $1.05 billion, reflecting its size and market presence. With a trading volume of 365,074 shares, the stock shows active investor interest. This level of trading activity can influence the stock's price movements and overall market perception.